Maca Root and African Mango: What Their Own Studies Measured, and What They're Worth at 15.47 mg Total
Maca (Lepidium meyenii) Root Extract and African Mango (Irvingia gabonensis) Seed Extract are printed first and second among the twenty-one names in Hawaiian Harmony's 15.47 mg blend. FDA's descending-order rule means neither can be outweighed by anything that follows — but it does not mean either one is large. This post sets the ranking question aside and asks what each ingredient's own separate research literature actually measured, then compares those numbers to what this label's arithmetic allows.
Two names, two very different amounts of research
Maca sits first in the blend, meaning its ceiling is the entire 15.47 mg — it could, in principle, be nearly the whole blend, though the label gives no way to confirm that it is. African mango sits second, so its ceiling is half of that, 7.74 mg. Both carry a concentrate mark: maca is noted ^, a 20:1 extract equivalent; African mango is noted with the label's " symbol, which the footnote defines as a 10:1 extract equivalent — a lower concentration ratio than every other marked ingredient on this label, and the only ingredient to carry it. This site's ingredients page already flags that the label reuses its asterisk glyph for two different footnotes, once for the %DV basis and again for this 10:1 note next to African mango specifically; that ambiguity is set aside here in favour of a more useful question — what does the actual clinical literature on each of these two ingredients say, independent of this label?
| Name | Position | Concentrate | Ceiling here |
|---|---|---|---|
| Maca (Lepidium meyenii) Root Extract | 1 of 21 | 20:1 | ≤ 15.47 mg |
| African Mango (Irvingia gabonensis) Seed Extract | 2 of 21 | 10:1 | ≤ 7.74 mg |
Maca: four trials found, in seventeen years of searching
Maca is a Peruvian Andean plant in the brassica (mustard) family, and its root is the part used. A 2010 systematic review, published in BMC Complementary and Alternative Medicine, searched seventeen separate databases from their inception through April 2010 for randomised controlled trials testing any form of maca against placebo, for sexual function in either healthy people or patients with sexual dysfunction. After that exhaustive search, exactly four RCTs met the inclusion criteria. Two of the four found a significant positive effect — one in healthy menopausal women, one on sexual desire in healthy adult men. A third, in healthy competitive cyclists, found no effect. A fourth, in men with diagnosed erectile dysfunction, found a significant effect using the International Index of Erectile Function-5 questionnaire. The review's own conclusion is carefully worded: limited evidence for the effectiveness of maca in improving sexual function,
with the total number of trials, total sample size and average methodological quality all described as too limited to draw firm conclusions, and a call for more rigorous studies.
That review's abstract does not itemise the exact dose used in each of the four trials. What can be said with a source this site has already cited — the same clinical monograph referenced on the ingredients page — is that human maca trials generally use gram-scale doses of gelatinised maca root, in the range of roughly 1.5 to 3 grams a day over about twelve weeks, with one trial reporting 1,500 mg as not effective and 3,000 mg as effective in a sexual-dysfunction context linked to SSRI use.
Hawaiian Harmony's maca ceiling is the largest possible in the entire blend: 15.47 mg, if maca were effectively the whole thing. Even at that theoretical maximum, 15.47 mg is 1.03% of the smallest gram-scale figure in that monograph range, 1,500 mg — a number already worked out on this site's ingredients page and repeated here because it is the ceiling that matters for this specific question. Read the 20:1 concentrate note in the label's favour and multiply the whole 15.47 mg back out to raw root, and the result is 309.4 mg of starting plant material — still roughly one-fifth of the smallest dose in the cited research, and that 309.4 mg has to be shared with whatever amount of the other twenty names is not, in reality, zero.
African mango: real effects in small trials, then a caveat from two reviews
African mango's research history runs in a fairly clear line. The earliest relevant human trial, published in Lipids in Health and Disease in 2005, was a double-blind randomised study of 40 obese subjects in Cameroon: 28 received 1.05 g of Irvingia gabonensis seed three times a day (3.15 g/day total) for one month, while 12 received placebo on the same schedule. The treatment group's body weight fell by a mean of 5.26%, versus 1.32% for placebo, a significant difference, alongside significant improvements in total cholesterol, LDL, triglycerides and HDL.
A follow-up 2009 trial, also in Lipids in Health and Disease, tested a specific branded extract called IGOB131 in 102 overweight or obese volunteers over ten weeks, dosed at 150 mg twice daily before meals — 300 mg a day. That trial reported significant improvements not just in body weight, body fat and waist circumference, but across a wider metabolic panel: total cholesterol, LDL, blood glucose, C-reactive protein, adiponectin and leptin, all moving favourably against placebo.
Two independent systematic reviews have since looked back across this literature as a whole, and both add an important caveat the individual trials do not volunteer on their own. A 2013 review in the Journal of Dietary Supplements located three RCTs in total (essentially this same small body of work) and found that all three had flaws in the reporting of their methodology.
Despite every included trial reporting statistically significant weight reductions, the review's conclusion was that the evidence is unproven
and that African mango cannot be recommended as a weight loss aid,
specifically because of that reporting-quality problem rather than because the results themselves were negative. A more recent 2020 meta-analysis in the Journal of the American College of Nutrition pooled five RCTs and found significant benefits for weight, body fat and several lipid markers — but reported that four of the five trials carried a high risk of bias, and that the single trial rated low risk of bias did not find a significant difference from placebo.
What the mango ceiling is worth against those doses
Hawaiian Harmony's African mango ceiling is 7.74 mg of a 10:1 concentrate — the least-concentrated marked ingredient on the whole label, and second position overall. Set against the branded IGOB131 dose used in the 2009 trial, a single 150 mg dose, 7.74 mg works out to 5.16% of one dose, or 2.58% of the full 300 mg daily amount used in that trial. Set against the earlier 2005 trial's 3.15 g daily total, 7.74 mg is 0.25% of it. Read the label's 10:1 note in the most generous direction and multiply 7.74 mg of concentrate back out to raw seed material, and the result is 77.4 mg — still roughly half of one single 150 mg IGOB131 dose, and the two figures are not strictly comparable anyway, because 77.4 mg would be raw seed material rather than the already-processed branded extract the trial actually used. This site prints that number as an illustration of scale, not as a claim that the two are interchangeable.
Both ceilings, side by side
| Name | Ceiling | Research dose | Ceiling as % of research dose |
|---|---|---|---|
| Maca Root Extract | 15.47 mg | 1,500–3,000 mg/day, gelatinised root, ≈12 weeks | 1.03% |
| African Mango Seed Extract | 7.74 mg | 150 mg per dose / 300 mg per day, IGOB131 extract, 10 weeks (Ngondi 2009) | 5.16% / 2.58% |
Both figures use the smallest published research amount available for each ingredient, which is the reading most generous to the label — the same convention this site's ingredients page uses throughout. Neither ingredient's ceiling reaches even 6% of the smallest dose its own cited research used, and that is before accounting for the fact that maca's 15.47 mg ceiling assumes it is effectively the entire blend, which nothing on this label confirms.
Why a positive trial result is not the end of the question
It would be easy to read the individual trial numbers above — a 5.26% weight loss, a significant IIEF-5 improvement — and stop there. The two systematic reviews exist precisely because stopping there is a mistake. For African mango, the 2013 review's finding is not that the trials showed no effect; it is that the trials showing an effect were not reported well enough to trust the size of that effect, and the 2020 meta-analysis adds that the one trial built well enough to trust on its own terms did not confirm the pooled result. For maca, the 2010 review's finding is not that maca does nothing; it is that four trials, spread across mixed populations and mixed outcomes, is not enough evidence to generalise from, however the review's authors themselves have said so directly. This is the same posture this site takes toward gymnema and several of the other blend ingredients on the ingredients page: a result reported once, in a small trial, is a data point, not a settled fact, and the number of trials behind either of these two names is still small enough to count on one hand.
The bottom line
Maca and African mango are the two largest-ranked names in Hawaiian Harmony's blend by label position, and both have real published human trials behind them — more, in African mango's case, than most of the other nineteen names on this label can claim. But rank is not amount, and neither ingredient's calculated ceiling, even read in the most generous way the label's own concentrate notes allow, reaches the doses used in the trials that produced their positive results. Maca's ceiling is about one-hundredth of the smallest studied daily amount; African mango's is a low single-digit percentage of the branded extract dose that produced its most-cited result, and the two independent reviews of that same African mango literature both add that even the studies setting that benchmark carry real methodological caveats. First and second on a label is a statement about order, not a statement about dose, and this label does not print the dose for either one.
Three questions this arithmetic tends to raise
If maca is first on the label, doesn't that mean it's probably the biggest part of the blend? It means maca is at least as large as every name after it, which is a different claim. First position sets no floor by itself — a label can legally print a blend where the first name is barely larger than the second, or one where the first name is nearly the entire blend, and this printed order cannot distinguish between those two very different realities. All this site can calculate is the ceiling: maca cannot weigh more than 15.47 mg, because nothing weighs more than the whole blend. Whether it weighs 15 mg or 1.5 mg, the label does not say.
Why does African mango get more space here than most of the other nineteen names? Because it has more independent human trial data behind it than almost any other name on this label — two primary RCTs and two separate systematic reviews of the wider literature, which is unusual for a proprietary-blend ingredient. That is exactly why the caveats attached to that data are worth spelling out in full: more evidence is only useful if its quality is also examined, and the two systematic reviews cited above did that examination and both flagged real limitations even while confirming the direction of the effect.
Does the 10:1 note on African mango mean it is a weaker ingredient than something marked 20:1? Not by itself. A concentration ratio describes the manufacturing process — how many parts of raw plant went into making one part of the extract — not the potency or effectiveness of the finished material. A 10:1 concentrate is less concentrated than a 20:1 concentrate by definition, but neither ratio states what compound was concentrated, at what percentage, or whether that compound is the one responsible for any effect seen in a clinical trial. This site's ingredients page makes the same point about every concentrate mark on this label: a ratio is not a standardisation.
Sources
- Maca (L. meyenii) for improving sexual function: a systematic reviewShin BC, Lee MS, Yang EJ, Lim HS, Ernst E. BMC Complement Altern Med. 2010;10:44. PMID 20691074Seventeen databases searched through April 2010; only four RCTs met inclusion criteria. Two found significant positive effects on sexual function/desire, one found no effect, one found a significant effect in erectile dysfunction. Conclusion: limited evidence, more rigorous studies warranted.
- Maca — clinical monographDrugs.com natural products database1.5 to 3 g/day of gelatinised maca root over 12 weeks in human trials; 1,500 mg reported not effective and 3,000 mg effective in one SSRI-related trial. Already cited on this site's ingredients page.
- The effect of Irvingia gabonensis seeds on body weight and blood lipids of obese subjects in CameroonNgondi JL, Oben JE, Minka SR. Lipids Health Dis. 2005;4:12. PMID 159167091.05 g three times daily (3.15 g/day) for one month; treatment group lost 5.26% body weight versus 1.32% for placebo, with significant lipid improvements.
- IGOB131, a novel seed extract of the West African plant Irvingia gabonensis, significantly reduces body weight and improves metabolic parameters in overweight humansNgondi JL, Etoundi BC, Nyangono CB, Mbofung CM, Oben JE. Lipids Health Dis. 2009;8:7. PMID 19254366150 mg twice daily (300 mg/day) of branded IGOB131 extract in 102 volunteers over 10 weeks; significant improvements in weight, body fat, waist circumference and multiple metabolic markers.
- The efficacy of Irvingia gabonensis supplementation in the management of overweight and obesity: a systematic review of randomized controlled trialsOnakpoya I, Davies L, Posadzki P, Ernst E. J Diet Suppl. 2013;10(1):29-38. PMID 23419021Three RCTs identified, all with methodological reporting flaws; despite significant weight results in each, the review concludes the effect is unproven and the ingredient cannot be recommended as a weight-loss aid on current evidence.
- The Effects of Irvingia gabonensis Seed Extract Supplementation on Anthropometric and Cardiovascular Outcomes: A Systematic Review and Meta-AnalysisLee J, Chung M, Fu Z, Choi J, Lee HJ. J Am Coll Nutr. 2020;39(5):388-396. PMID 31855111Five RCTs pooled; significant benefits for weight and lipid markers overall, but four of five trials had high risk of bias, and the single low-risk-of-bias trial did not find a significant difference from placebo.